AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10028979 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 188
Study 7745043 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-culture with human skin fibroblast monolayers
Number of subjects: 0
Study 7745043 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal semen analysis
Number of subjects: 0
Study 7745043 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormal semen analysis
Number of subjects: 0
Study 2387277 — intervention group
Group type: COMPARATOR
Intervention: Soy sauce added to soy flour meal
Number of subjects: 0
Study 2387277 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy sauce added to rice meal
Number of subjects: 0
Study 2387277 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy sauce added to rice meal alone
Number of subjects: 0
Study 2387277 — intervention group
Group type: COMPARATOR
Intervention: Lactic acid added to rice
Number of subjects: 0
Study 7148735 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspartame plus monosodium L-glutamate (34 mg/kg body weight)
Number of subjects: 6
Study 7148735 — intervention group
Group type: COMPARATOR
Intervention: Control meal (no additions)
Number of subjects: 6
Study 31694107 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACT) with Gemcitabine+Cisplatin three weeks regimen
Number of subjects: 176
Study 31694107 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (ACT)
Number of subjects: 176
Study 28248887 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with remifentanil 1.0 μg/kg
Number of subjects: 3
Study 28248887 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with remifentanil 1.5 μg/kg
Number of subjects: 3
Study 28248887 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane with remifentanil 2.0 μg/kg
Number of subjects: 3
Study 26546068 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (aerobic and strength training 3-4 days/week at 60% HRres, 50% RM for moderate intensity; 80% HRres, 70% RM for vigorous intensity)
Number of subjects: 150
Study 26546068 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise group
Number of subjects: 150
Study 24153171 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (open discectomy)
Number of subjects: 1244
Study 24153171 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative care
Number of subjects: 1244
Study 20883985 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment for 4 years
Number of subjects: 38
Study 20883985 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 38
Study 18726908 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (D2/D3 agonist)
Number of subjects: 0
Study 18726908 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17522474 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US)
Number of subjects: 62
Study 17522474 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 62
Study 17522474 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney/Ureter/Bladder X-ray (KUB)
Number of subjects: 62
Study 17522474 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of US+CT+KUB
Number of subjects: 62
Study 17522474 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of US+CT
Number of subjects: 62
Study 17522474 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of KUB+CT
Number of subjects: 62
Study 17522474 — intervention group
Group type: EXPERIMENTAL
Intervention: Two exams suggesting NC diagnosis (including CT)
Number of subjects: 62
Study 17522474 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of exams together
Number of subjects: 62
Study 17522474 — intervention group
Group type: EXPERIMENTAL
Intervention: First and second reviews by observers
Number of subjects: 62
Study 16213310 — intervention group
Group type: EXPERIMENTAL
Intervention: Taguchi technique
Number of subjects: 144
Study 16213310 — intervention group
Group type: COMPARATOR
Intervention: Modified Lich-Gregoir technique
Number of subjects: 144
Study 12322866 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized homeopathic therapy
Number of subjects: 45
Study 10524821 — intervention group
Group type: EXPERIMENTAL
Intervention: PCL reconstruction with BPTB autograft
Number of subjects: 70
Study 10524821 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI evaluation of tunnel placement
Number of subjects: 70
Study 10524821 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical evaluation using KT-2000 arthrometer
Number of subjects: 70
Study 7563259 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltamethrin impregnated bednets
Number of subjects: 480
Study 7563259 — intervention group
Group type: COMPARATOR
Intervention: Control (no nets)
Number of subjects: 480
Study 2261735 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-8980
Number of subjects: 145
Study 371903 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbimide (CC) 0.7 mg/kg
Number of subjects: 5
Study 371903 — intervention group
Group type: COMPARATOR
Intervention: Ethanol 0.125 gm/kg
Number of subjects: 5
Study 371903 — intervention group
Group type: COMPARATOR
Intervention: Ethanol 0.25 gm/kg
Number of subjects: 5
Study 371903 — intervention group
Group type: COMPARATOR
Intervention: Ethanol 0.5 gm/kg
Number of subjects: 5
Study 31913227 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiologic VMS
Number of subjects: 14
Study 31187863 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA + AA (200 mg each)
Number of subjects: 377
Study 31187863 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 377
Study 27787893 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity intervention (video plus home-based educational session)
Number of subjects: 443
Study 27787893 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity intervention (video delivered to participants' homes)
Number of subjects: 443
Study 27787893 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 443
Study 25951761 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening heart failure (WHF)
Number of subjects: 3691
Study 25951761 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening heart failure (WHF) requiring intravenous inotropes or mechanical therapy
Number of subjects: 3691
Study 25951761 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening heart failure (WHF) treated with intravenous loop diuretic alone
Number of subjects: 3691
Study 23942596 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care
Number of subjects: 169
Study 23942596 — intervention group
Group type: COMPARATOR
Intervention: Palliative care
Number of subjects: 169
Study 22152246 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal albendazole (L-ABZ)
Number of subjects: 218
Study 22152246 — intervention group
Group type: COMPARATOR
Intervention: Tablet albendazole (T-ABZ)
Number of subjects: 218
Study 22152246 — intervention group
Group type: EXPERIMENTAL
Intervention: L-ABZ and T-ABZ
Number of subjects: 218
Study 18847329 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg orally once a day for 3 days
Number of subjects: 12
Study 18847329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17118687 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) treatment (200 microg/day for the first month, then 400 microg/day for men and 600 microg/day for women thereafter)
Number of subjects: 40
Study 17118687 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) treatment
Number of subjects: 40
Study 17118687 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14552082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri-sodium citrate as anticoagulant
Number of subjects: 0
Study 14552082 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowering dialysis fluid bicarbonate concentration from 37 mmol/l to 25 mmol/l
Number of subjects: 0
Study 14552082 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusting dialysis fluid sodium concentration from 140 mmol/l to 132 mmol/l
Number of subjects: 0
Study 14552082 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacing glass bottles with polyvinylchloride bags
Number of subjects: 0
Study 10752824 — intervention group
Group type: EXPERIMENTAL
Intervention: Olprinone (OLP) 0.3 microg/kg/min for 2 hrs
Number of subjects: 29
Study 10752824 — intervention group
Group type: COMPARATOR
Intervention: Milrinone (MIL) 0.5 microg/kg/min for 2 hrs
Number of subjects: 29
Study 10752824 — intervention group
Group type: COMPARATOR
Intervention: Amrinone (AMR) 10 microg/kg/min for 2 hrs
Number of subjects: 29
Study 10752824 — intervention group
Group type: EXPERIMENTAL
Intervention: Olprinone (OLP)
Number of subjects: 29
Study 10752824 — intervention group
Group type: COMPARATOR
Intervention: Milrinone (MIL)
Number of subjects: 29
Study 10752824 — intervention group
Group type: COMPARATOR
Intervention: Amrinone (AMR)
Number of subjects: 29
Study 9557113 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative patients after extensive resections
Number of subjects: 30
Study 9557113 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients after pancreatoduodenectomy
Number of subjects: 30
Study 9557113 — intervention group
Group type: COMPARATOR
Intervention: Patients awaiting sinister operations (control group)
Number of subjects: 30
Study 1403068 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam (Az)
Number of subjects: 34
Study 1403068 — intervention group
Group type: COMPARATOR
Intervention: Colistin plus Neomycin (CN)
Number of subjects: 34
Study 4073858 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (80 mg/kg once daily after an initial dose of 100 mg/kg)
Number of subjects: 36
Study 4073858 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin plus chloramphenicol (conventional dosages)
Number of subjects: 36
Study 4073858 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 36
Study 4073858 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin plus chloramphenicol
Number of subjects: 36
Study 31835959 — intervention group
Group type: EXPERIMENTAL
Intervention: QR code-based information (graphic and text)
Number of subjects: 55
Study 31835959 — intervention group
Group type: COMPARATOR
Intervention: Current bottle label information
Number of subjects: 55
Study 31835959 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger adults
Number of subjects: 55
Study 31835959 — intervention group
Group type: COMPARATOR
Intervention: Older adults
Number of subjects: 55
Study 31033362 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 140
Study 31033362 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitor (ACEI)
Number of subjects: 140
Study 31033362 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen-progestin therapy (EPT)
Number of subjects: 140
Study 30942964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium tripolyphosphate 2% tablets
Number of subjects: 66
Study 30942964 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium tripolyphosphate 0.65% tablets
Number of subjects: 66
Study 30942964 — intervention group
Group type: COMPARATOR
Intervention: No-tablet control
Number of subjects: 66
Study 26988368 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB) with ropivacaine plus plain lubricant
Number of subjects: 0
Study 26988368 — intervention group
Group type: COMPARATOR
Intervention: Dorsal penile nerve block (DPNB) with saline (tetracaine gel group)
Number of subjects: 0
Study 26988368 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB) with ropivacaine plus tetracaine gel (combination group)
Number of subjects: 0
Study 26988368 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal penile nerve block (DPNB)
Number of subjects: 0
Study 24608924 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-2α therapy
Number of subjects: 17
Study 24608924 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-2α combined with 5-fluorouracil
Number of subjects: 17
Study 22964609 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 48
Study 22964609 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine
Number of subjects: 48
Study 19647964 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided infiltration of local anaesthetic and corticoid
Number of subjects: 20
Study 19647964 — intervention group
Group type: COMPARATOR
Intervention: Palpation-guided infiltration of local anaesthetic and corticoid
Number of subjects: 20
Study 19647964 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided infiltration
Number of subjects: 20
Study 19647964 — intervention group
Group type: COMPARATOR
Intervention: Palpation-guided infiltration
Number of subjects: 20
Study 18665163 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (G) added to paclitaxel (T) following epirubicin (E) and cyclophosphamide (C)
Number of subjects: 135
Study 18665163 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (T) following epirubicin (E) and cyclophosphamide (C) without gemcitabine
Number of subjects: 135
Study 15942766 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 min run at 55% of VO2max
Number of subjects: 8
Study 15942766 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 min run at 55% of VO2max
Number of subjects: 8
Study 15942766 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 min run at 55% of VO2max
Number of subjects: 8
Study 15942766 — intervention group
Group type: COMPARATOR
Intervention: Resting session
Number of subjects: 8
Study 15942766 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 min run
Number of subjects: 8
Study 15942766 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 min run
Number of subjects: 8
Study 12626679 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading (16%, 33%, 50% of body weight)
Number of subjects: 0
Study 12626679 — intervention group
Group type: EXPERIMENTAL
Intervention: Unloading (10%, 20%, 30% of body weight)
Number of subjects: 0
Study 12626679 — intervention group
Group type: COMPARATOR
Intervention: Non-loaded control condition
Number of subjects: 0
Study 12626679 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading
Number of subjects: 0
Study 12626679 — intervention group
Group type: EXPERIMENTAL
Intervention: Unloading
Number of subjects: 0
Study 12626679 — intervention group
Group type: EXPERIMENTAL
Intervention: Loading conditions
Number of subjects: 0
Study 10584133 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/m2 amifostine intravenously prior to high-dose radioiodine treatment
Number of subjects: 50
Study 10584133 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline solution (control)
Number of subjects: 50
Study 8561761 — intervention group
Group type: EXPERIMENTAL
Intervention: Group treatment for hypochondriasis
Number of subjects: 14
Study 8561761 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control
Number of subjects: 14
Study 1667511 — intervention group
Group type: EXPERIMENTAL
Intervention: Astragalus membranaceus (AM) intravenous 24 g/d infused into 5% glucose 250 ml
Number of subjects: 67
Study 1667511 — intervention group
Group type: COMPARATOR
Intervention: 5% glucose 250 ml
Number of subjects: 67
Study 6406649 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Parenteral Nutrition (TPN)
Number of subjects: 38
Study 6406649 — intervention group
Group type: COMPARATOR
Intervention: Standard Enteral Nutrition (SEN)
Number of subjects: 38
Study 31373982 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 17
Study 31373982 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 17
Study 31373982 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 17
Study 29654840 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture for 20 minutes/day, for 15 days/month, for 90 days
Number of subjects: 60
Study 29654840 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupuncture)
Number of subjects: 60
Study 26858433 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) administered intranasally
Number of subjects: 0
Study 26858433 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intranasally
Number of subjects: 0
Study 26858433 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP)
Number of subjects: 0
Study 23909858 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic intervention + treatment as usual (TAU)
Number of subjects: 92
Study 23909858 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 92
Study 22379116 — intervention group
Group type: EXPERIMENTAL
Intervention: Unacylated ghrelin (UAG) infusion (1.0 μg/kg per h)
Number of subjects: 8
Study 22379116 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study 20639355 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (2×500 mg/day)
Number of subjects: 70
Study 20639355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 18520682 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose TDF (300 mg)/FTC (200 mg)
Number of subjects: 397
Study 18520682 — intervention group
Group type: COMPARATOR
Intervention: No intervention in labor (Control)
Number of subjects: 397
Study 18520682 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose TDF/FTC
Number of subjects: 397
Study 18520682 — intervention group
Group type: COMPARATOR
Intervention: No antenatal ZDV (Control)
Number of subjects: 397
Study 18520682 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF/FTC
Number of subjects: 397
Study 18520682 — intervention group
Group type: EXPERIMENTAL
Intervention: Other antiretroviral drugs
Number of subjects: 397
Study 15948007 — intervention group
Group type: EXPERIMENTAL
Intervention: Interictal brain perfusion 99mTc‐ethylcysteinate dimer (ECD) SPECT in PKC patients
Number of subjects: 16
Study 15948007 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 16
Study 12390715 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% ropivacaine (Group R, n=10)
Number of subjects: 20
Study 12390715 — intervention group
Group type: COMPARATOR
Intervention: 0.125% bupivacaine (Group B, n=10)
Number of subjects: 20
Study 12390715 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group R and Group B)
Number of subjects: 20
Study 9932994 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2% twice daily (n = 466)
Number of subjects: 837
Study 9932994 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% twice daily (n = 371)
Number of subjects: 837
Study 8850571 — intervention group
Group type: EXPERIMENTAL
Intervention: High contextual interference group (practised the skill on alternate sides)
Number of subjects: 16
Study 8850571 — intervention group
Group type: COMPARATOR
Intervention: Low contextual interference group (followed U'ren's recommendations)
Number of subjects: 16
Study 1967597 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (0.5 mg, incremented to a final dose of 2.5 +/- 1.7 mg)
Number of subjects: 38
Study 1967597 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3.1 +/- 2.0 mg)
Number of subjects: 38
Study 7438696 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide (60 mg)
Number of subjects: 0
Study 7438696 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine (120 mg)
Number of subjects: 0
Study 7438696 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31591826 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine on top of guideline-directed medical therapy (GDMT)
Number of subjects: 3357
Study 28631527 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone 4mg/1mg
Number of subjects: 80
Study 28631527 — intervention group
Group type: COMPARATOR
Intervention: Methadone 30mg
Number of subjects: 80
Study 28631527 — intervention group
Group type: COMPARATOR
Intervention: Methadone/lofexidine
Number of subjects: 80
Study 25864745 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Supplement (FS) alone
Number of subjects: 45
Study 25864745 — intervention group
Group type: COMPARATOR
Intervention: Thyroid hormones alone
Number of subjects: 45
Study 25864745 — intervention group
Group type: EXPERIMENTAL
Intervention: FS plus thyroid hormones
Number of subjects: 45
Study 23758458 — intervention group
Group type: EXPERIMENTAL
Intervention: Pastinject
Number of subjects: 29
Study 23758458 — intervention group
Group type: EXPERIMENTAL
Intervention: Bi‐directional spiral
Number of subjects: 29
Study 23758458 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure syringe
Number of subjects: 29
Study 23758458 — intervention group
Group type: EXPERIMENTAL
Intervention: Pastinject and Pressure syringe
Number of subjects: 29
Study 21129755 — intervention group
Group type: EXPERIMENTAL
Intervention: Early and high AA (2 g/kg/d, increased by 1 g/kg daily to 4 g/kg/d)
Number of subjects: 62
Study 21129755 — intervention group
Group type: COMPARATOR
Intervention: Standard AA (0.5 g/kg/d, increased by 0.5 g/kg daily to 3 g/kg/d)
Number of subjects: 62
Study 19684408 — intervention group
Group type: EXPERIMENTAL
Intervention: Spousal donor grafts
Number of subjects: 445
Study 19684408 — intervention group
Group type: COMPARATOR
Intervention: Other LUD grafts
Number of subjects: 445
Study 17895439 — intervention group
Group type: EXPERIMENTAL
Intervention: Community occupational therapy (10 sessions over 5 weeks)
Number of subjects: 135
Study 17895439 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 135
Study 15298427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (30 mg/kg)
Number of subjects: 60
Study 15298427 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 60
Study 11830754 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 0
Study 11084131 — intervention group
Group type: EXPERIMENTAL
Intervention: MIST VR (virtual reality training)
Number of subjects: 24
Study 11084131 — intervention group
Group type: COMPARATOR
Intervention: Normal laparoscopic imaging
Number of subjects: 24
Study 11084131 — intervention group
Group type: COMPARATOR
Intervention: Randomly alternating imaging (y-axis inverted and normal laparoscopic)
Number of subjects: 24